These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35393160)

  • 1. Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142.
    Di Lorenzo G; Buonerba C
    Eur Urol; 2022 Jul; 82(1):e17. PubMed ID: 35393160
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono J
    Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    van Soest RJ; de Wit R
    Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    Roviello G; Generali D; Petrioli R
    Eur Urol; 2017 Feb; 71(2):e55. PubMed ID: 27543166
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono JS
    Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1846. PubMed ID: 24210085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Mahal BA; D'Amico AV; Nguyen PL
    Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
    Rizzo A; Mollica V; Massari F
    Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Shore ND; Dearnaley D; Tombal B
    Eur Urol; 2020 Nov; 78(5):e196-e197. PubMed ID: 32838997
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Vilaseca A; Ribal MJ
    Eur Urol; 2022 Nov; 82(5):573. PubMed ID: 35907664
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Chen K; McVey A; Kasivisvanathan V; Jenjitranant P; Azad A; Murphy DG
    Eur Urol; 2022 Jul; 82(1):146-147. PubMed ID: 35346516
    [No Abstract]   [Full Text] [Related]  

  • 12. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.
    Varkaris A; Stevens J; Ono Y; Balk SP; Bellmunt J
    JCO Precis Oncol; 2022 Feb; 6():e2100091. PubMed ID: 35201849
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Wei Y; Ye D; Zhu Y
    Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
    Suzuki H; Shin T; Fukasawa S; Hashine K; Kitani S; Ohtake N; Shibayama K; Tran N; Mundle S; Fizazi K; Matsubara N
    Jpn J Clin Oncol; 2020 Jul; 50(7):810-820. PubMed ID: 32188988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darolutamide in Metastatic Prostate Cancer.
    Bowling GC; Dimitrakoff JD
    N Engl J Med; 2022 Jun; 386(24):2344. PubMed ID: 35704493
    [No Abstract]   [Full Text] [Related]  

  • 19. Darolutamide in Metastatic Prostate Cancer.
    Turco F; Tucci M; Buttigliero C
    N Engl J Med; 2022 Jun; 386(24):2344. PubMed ID: 35704492
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.